Adam Schwartz
Medical · Phoenix, AZNPI 1528121266
Payments from drug & device makers
Across 572 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Sanofi$923
- Boehringer Ingelheim$693
- Regeneron Healthcare Solutions, Inc.$656
- Grifols USA, LLC$611
- plus $6K from 41 others
What the payments were for
- Consulting fees$1071%
- Food & beverage$11,98897%
- Education$2962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$546
- Brinsupri$350
- BREZTRI$306
- AIRSUPRA$306
- FASENRA$178
- Arikayce$175
- SYMBICORT$128
- IMFINZI$128
- Inspire Upper Airway Stimulation System$121
- Nalu Neurostimulation System$114
How this compares
$12,391 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 256 | $191,856 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $43,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $42,867 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $22,671 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $17,272 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $10,735 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $10,558 |
| Arnuity ElliptaFluticasone Furoate | 21 | $9,176 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $7,203 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,584 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 162 | $3,797 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,407 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,996 |
| Montelukast Sodium | 145 | $1,394 |
| Fluconazole | 24 | $1,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,651 | $277,681425 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,519 | $58,187109 claims |
| Boehringer IngelheimStiolto Respimat | $693 | $17,27230 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $7,20317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.
Other medical in Phoenix
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
- Lakeisha ColterPhoenix$48K
- Amy IngersollPhoenix$42K
- Ty NielsonPhoenix$18K
- Brittany SilvermanPhoenix$16K
- John RimerPhoenix$15K
- Rana AoufePhoenix$14K
- Rebecca RowenPhoenix$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.